Scenes reactivate novel mechanisms of addictive memory through inhibition-desuppression neural circuits
Time of Update: 2023-02-02
Recently, the research work of Professor Zheng Ping's research group of the Institute of Brain Sciences/State Key Laboratory of Medical Neurobiology of Fudan University has discovered a new mechanism by which scenes reactivate addictive memory through the inhibition-desuppression neural circuit.
Top20 Throat Chinese Proprietary Medicine Announced: Lanqin Oral Liquid, Silver Granules, Liushen Pill
Time of Update: 2023-01-01
Exclusive variety list In recent years, the total market share of the top 20 proprietary Chinese medicine products in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as Chinese public medical institutions) has exceeded 90%.
The Sound of Silence Lights Up the World - Colorectal Cancer ESMO Highlights Review
Time of Update: 2022-10-14
prefaceAlthough the results of the 2022 European Society for Internal Oncology Annual Meeting (ESMO) in the field of coloral cancer (CRC) treatment, which ended on September 13, are missing large phas
InnoCare Announces the Acceptance of the Marketing Application of Tafasitamab in Combination with Lenalidomide in the Treatment of Relapsed/Refractory DLBCL in Hong Kong
Time of Update: 2022-09-07
About Nuocheng JianhuaNuocheng Jianhua (Hong Kong Stock Exchange Code: 09969) is a high-tech biopharmaceutical company in the commercialization stage, focusing on the development of a class of new drugs for the treatment of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma and solid tumors.
Time of Update: 2022-08-15
In the past 5 trading days, the stock price of Tianjing Bio has been falling continuously, and the phase II clinical trial (CP-MGA271-06) of its partner MacroGenics' core product B7-H3 monoclonal ant
The second batch of the 2021 national drug standard improvement project catalog was announced, containing 9 types of pharmaceutical excipients and 2 general testing methods for pharmaceutical
Time of Update: 2021-12-24
Drafting of Guidelines for Biological Evaluation and Test Selection of Pharmaceutical Packaging Materials Research purposes research content Drafting of the Method for Determination of Aromatic Primary Amine Extraction in Pharmaceutical Packaging Materials Research purposes research content In order to ensure the smooth progress of the national drug standard improvement work in 2021, the National Pharmacopoeia Commission has made requirements on issues such as subject management .
The Guangdong Super League is coming
Time of Update: 2021-08-07
Different selection conditions are given: In the over-evaluated B purchase order, the order of "comparable unit price" is determined from low to high, and the top X% ratio (rounded to retain The number of shortlisted companies is 6 at most .
Buchang Pharmaceuticals lacosamide tablets obtained a drug registration certificate issued by the State Food and Drug Administration
Time of Update: 2021-07-07
, a wholly-owned subsidiary of the company, has recently received the "Drug Registration Certificate" for lacosamide tablets approved and issued by the National Medical Products Administration .
14 million in research and development expenses on lacosamide tablets .
Renfu Medicine HW021199 tablets are approved for clinical use in the treatment of idiopathic pulmonary fibrosis
Time of Update: 2021-07-07
On April 30, Renfu Medicine issued an announcement stating that recently, its subsidiary Hubei Biomedical Industry Technology Research Institute Co.
(referred to as the "Research Institute Co.
Only two drugs, nintedanib and pirfenidone, are approved for the treatment of idiopathic pulmonary fibrosis .
Overview of the clinical pipeline of cancer cell therapy in 2021
Time of Update: 2021-06-30
In the past year, the number of allogeneic drugs in preclinical and clinical phase I development has increased significantly (48% and 42%, respectively), while growth rates in 2020 are 80% and 95%, respectively .
Keystone Pharmaceuticals anti-PD-L1 monoantigen is intended to be included in the breakthrough treatment varieties
Time of Update: 2021-03-09
Source: Pharmaceutical Mission China National Drug Administration Drug Review Center (CDE) the latest publicity, Keystone Pharmaceuticals Class 1 bio-new drug recombinant anti-PD-L1 human monoclonal antibody injection is intended to be included in the breakthrough treatment varieties, the proposed adaptation is: recurrence or refractory extraterrestrial natural killer cells / T cell lymphoma (R/R ENKTL).
Connbe: The hydrochloride bromoso injection was evaluated for generic consistency
Time of Update: 2021-01-31
On 12 January, Connbe announced receipt of the Drug SupplementAl Application Approval issued by NMPA for ammonia hydrochloride injections, which are evaluated through generic consistency.
date of disclosure of this announcement, the Company has invested approximately RMB6.28 million (unaudited) in research and development for the consistent evaluation of the drug.
Information Circular on Food Safety Supervision and Sampling of Zhejiang Market Supervision Administration (No. 23 of 2020
Time of Update: 2020-12-08
The specific situation notice is as follows: First, agricultural and veterinary drug residues exceeded the standard (i) Hangzhou United Huahua Group Co., Ltd. Deqing Zhongxing Road Century United China Supermarket sales of the label Hangzhou and Bee Garden Health Products Co., Ltd. production of eucalyptus honey, Nofluosa Star does not meet the national standards for food safety.
The overhaul of Chinese medicine tablets began, and many pharmacies were strictly investigated
Time of Update: 2020-11-18
"Pharmaceutical Network Industry Dynamics" Chinese medicine tablets is China's traditional Chinese medicine industry, with the industrialization and marketization of Traditional Chinese medicine cont
CSCO 2020 Look: What's the busiest PI, do you know
Time of Update: 2020-10-04
In the field of oncology in China, gastric cancer experts have "North Shen, South Li" Ya, "North Shen" refers to Professor Shen Lin of Peking University Cancer Hospital, "South Li" refers to The Shanghai Oriental Hospital well-known oncologist, former chairman of CSCO Professor Li Jin.